 | • レポートコード：MRC2-11QY12560 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はリソソーム蓄積症（LSD）治療薬のグローバル市場について調査・分析したレポートです。種類別（酵素補充療法、幹細胞治療、基質減少療法、その他）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別リソソーム蓄積症（LSD）治療薬の競争状況、市場シェア ・世界のリソソーム蓄積症（LSD）治療薬市場：種類別市場規模 2015年-2020年（酵素補充療法、幹細胞治療、基質減少療法、その他） ・世界のリソソーム蓄積症（LSD）治療薬市場：種類別市場規模予測 2021年-2026年（酵素補充療法、幹細胞治療、基質減少療法、その他） ・世界のリソソーム蓄積症（LSD）治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界のリソソーム蓄積症（LSD）治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米のリソソーム蓄積症（LSD）治療薬市場分析：米国、カナダ ・ヨーロッパのリソソーム蓄積症（LSD）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのリソソーム蓄積症（LSD）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のリソソーム蓄積症（LSD）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのリソソーム蓄積症（LSD）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Takeda、Pfizer、Sanofi、BioMarin Pharmaceutical、Actelion Ltd、Raptor Pharmaceutical、Protalix Biotherapeutics、Amicus Therapeutics ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Lysosomal storage disorders is a group of genetic metabolic diseases caused by enzyme deficiencies in various body cells.
The Gaucher’s Diseases indication segment is expected to be the most dominant segment in global lysosomal storage diseases therapeutics market.
Market Analysis and Insights: Global Lysosomal Storage Diseases Therapeutics Market
The global Lysosomal Storage Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Lysosomal Storage Diseases Therapeutics Scope and Market Size
Lysosomal Storage Diseases Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Lysosomal Storage Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Takeda
Pfizer
Sanofi
BioMarin Pharmaceutical
Actelion Ltd
Raptor Pharmaceutical
Protalix Biotherapeutics
Amicus Therapeutics
Market segment by Type, the product can be split into
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Other
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Lysosomal Storage Diseases Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Lysosomal Storage Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Enzyme Replacement Therapy
1.4.3 Stem Cell Therapy
1.4.4 Substrate Reduction Therapy
1.4.5 Other
1.5 Market by Application
1.5.1 Global Lysosomal Storage Diseases Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Lysosomal Storage Diseases Therapeutics Market Perspective (2015-2026)
2.2 Global Lysosomal Storage Diseases Therapeutics Growth Trends by Regions
2.2.1 Lysosomal Storage Diseases Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Lysosomal Storage Diseases Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Lysosomal Storage Diseases Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Lysosomal Storage Diseases Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Storage Diseases Therapeutics Players by Market Size
3.1.1 Global Top Lysosomal Storage Diseases Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Lysosomal Storage Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Lysosomal Storage Diseases Therapeutics Market Concentration Ratio
3.2.1 Global Lysosomal Storage Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Diseases Therapeutics Revenue in 2019
3.3 Lysosomal Storage Diseases Therapeutics Key Players Head office and Area Served
3.4 Key Players Lysosomal Storage Diseases Therapeutics Product Solution and Service
3.5 Date of Enter into Lysosomal Storage Diseases Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Lysosomal Storage Diseases Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
5.2 Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
6.2 Lysosomal Storage Diseases Therapeutics Key Players in North America (2019-2020)
6.3 North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
6.4 North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
7.2 Lysosomal Storage Diseases Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
7.4 Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
8.2 Lysosomal Storage Diseases Therapeutics Key Players in China (2019-2020)
8.3 China Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
8.4 China Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
9.2 Lysosomal Storage Diseases Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
9.4 Japan Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
10.2 Lysosomal Storage Diseases Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
11.2 Lysosomal Storage Diseases Therapeutics Key Players in India (2019-2020)
11.3 India Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
11.4 India Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Lysosomal Storage Diseases Therapeutics Market Size (2015-2020)
12.2 Lysosomal Storage Diseases Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Takeda
13.1.1 Takeda Company Details
13.1.2 Takeda Business Overview
13.1.3 Takeda Lysosomal Storage Diseases Therapeutics Introduction
13.1.4 Takeda Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020))
13.1.5 Takeda Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Lysosomal Storage Diseases Therapeutics Introduction
13.2.4 Pfizer Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Lysosomal Storage Diseases Therapeutics Introduction
13.3.4 Sanofi Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 BioMarin Pharmaceutical
13.4.1 BioMarin Pharmaceutical Company Details
13.4.2 BioMarin Pharmaceutical Business Overview
13.4.3 BioMarin Pharmaceutical Lysosomal Storage Diseases Therapeutics Introduction
13.4.4 BioMarin Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.4.5 BioMarin Pharmaceutical Recent Development
13.5 Actelion Ltd
13.5.1 Actelion Ltd Company Details
13.5.2 Actelion Ltd Business Overview
13.5.3 Actelion Ltd Lysosomal Storage Diseases Therapeutics Introduction
13.5.4 Actelion Ltd Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.5.5 Actelion Ltd Recent Development
13.6 Raptor Pharmaceutical
13.6.1 Raptor Pharmaceutical Company Details
13.6.2 Raptor Pharmaceutical Business Overview
13.6.3 Raptor Pharmaceutical Lysosomal Storage Diseases Therapeutics Introduction
13.6.4 Raptor Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.6.5 Raptor Pharmaceutical Recent Development
13.7 Protalix Biotherapeutics
13.7.1 Protalix Biotherapeutics Company Details
13.7.2 Protalix Biotherapeutics Business Overview
13.7.3 Protalix Biotherapeutics Lysosomal Storage Diseases Therapeutics Introduction
13.7.4 Protalix Biotherapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.7.5 Protalix Biotherapeutics Recent Development
13.8 Amicus Therapeutics
13.8.1 Amicus Therapeutics Company Details
13.8.2 Amicus Therapeutics Business Overview
13.8.3 Amicus Therapeutics Lysosomal Storage Diseases Therapeutics Introduction
13.8.4 Amicus Therapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020)
13.8.5 Amicus Therapeutics Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Lysosomal Storage Diseases Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Lysosomal Storage Diseases Therapeutics Revenue
Table 3. Ranking of Global Top Lysosomal Storage Diseases Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Lysosomal Storage Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Key Players of Stem Cell Therapy
Table 7. Key Players of Substrate Reduction Therapy
Table 8. Key Players of Other
Table 9. Global Lysosomal Storage Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Lysosomal Storage Diseases Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Lysosomal Storage Diseases Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Lysosomal Storage Diseases Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Lysosomal Storage Diseases Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Lysosomal Storage Diseases Therapeutics Players
Table 20. Global Lysosomal Storage Diseases Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Lysosomal Storage Diseases Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Lysosomal Storage Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Diseases Therapeutics as of 2019)
Table 23. Global Lysosomal Storage Diseases Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Lysosomal Storage Diseases Therapeutics Product Solution and Service
Table 26. Date of Enter into Lysosomal Storage Diseases Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Lysosomal Storage Diseases Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Lysosomal Storage Diseases Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Lysosomal Storage Diseases Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Lysosomal Storage Diseases Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 36. North America Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 38. North America Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 42. Europe Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 48. China Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 50. China Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 54. Japan Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 66. India Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 68. India Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Lysosomal Storage Diseases Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Lysosomal Storage Diseases Therapeutics Market Share (2019-2020)
Table 72. Central & South America Lysosomal Storage Diseases Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Lysosomal Storage Diseases Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Lysosomal Storage Diseases Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Lysosomal Storage Diseases Therapeutics Market Share by Application (2015-2020)
Table 76. Takeda Company Details
Table 77. Takeda Business Overview
Table 78. Takeda Product
Table 79. Takeda Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 80. Takeda Recent Development
Table 81. Pfizer Company Details
Table 82. Pfizer Business Overview
Table 83. Pfizer Product
Table 84. Pfizer Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 85. Pfizer Recent Development
Table 86. Sanofi Company Details
Table 87. Sanofi Business Overview
Table 88. Sanofi Product
Table 89. Sanofi Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 90. Sanofi Recent Development
Table 91. BioMarin Pharmaceutical Company Details
Table 92. BioMarin Pharmaceutical Business Overview
Table 93. BioMarin Pharmaceutical Product
Table 94. BioMarin Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 95. BioMarin Pharmaceutical Recent Development
Table 96. Actelion Ltd Company Details
Table 97. Actelion Ltd Business Overview
Table 98. Actelion Ltd Product
Table 99. Actelion Ltd Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 100. Actelion Ltd Recent Development
Table 101. Raptor Pharmaceutical Company Details
Table 102. Raptor Pharmaceutical Business Overview
Table 103. Raptor Pharmaceutical Product
Table 104. Raptor Pharmaceutical Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 105. Raptor Pharmaceutical Recent Development
Table 106. Protalix Biotherapeutics Company Details
Table 107. Protalix Biotherapeutics Business Overview
Table 108. Protalix Biotherapeutics Product
Table 109. Protalix Biotherapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 110. Protalix Biotherapeutics Recent Development
Table 111. Amicus Therapeutics Business Overview
Table 112. Amicus Therapeutics Product
Table 113. Amicus Therapeutics Company Details
Table 114. Amicus Therapeutics Revenue in Lysosomal Storage Diseases Therapeutics Business (2015-2020) (Million US$)
Table 115. Amicus Therapeutics Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lysosomal Storage Diseases Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Enzyme Replacement Therapy Features
Figure 3. Stem Cell Therapy Features
Figure 4. Substrate Reduction Therapy Features
Figure 5. Other Features
Figure 6. Global Lysosomal Storage Diseases Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Other Case Studies
Figure 10. Lysosomal Storage Diseases Therapeutics Report Years Considered
Figure 11. Global Lysosomal Storage Diseases Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions: 2020 VS 2026
Figure 13. Global Lysosomal Storage Diseases Therapeutics Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Lysosomal Storage Diseases Therapeutics Market Share by Players in 2019
Figure 16. Global Top Lysosomal Storage Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Diseases Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Lysosomal Storage Diseases Therapeutics Revenue in 2019
Figure 18. North America Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Lysosomal Storage Diseases Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
リソソーム蓄積症（LSD）の世界市場（～2026年） Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Dis…- リソソームα-グルコシダーゼの世界市場（～2026年） Market Analysis and Insights: Global Lysosomal Alpha Glucosidase Market The global Lysosomal Alpha Glucosidase market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Lysosomal Alpha Glucosidase Scope and Market Size Lysosomal…
- 多発性硬化症における幹細胞治療の世界市場（～2026年） Multiple sclerosis is a nervous system disease, triggered by unidentified environmental factors that adversely affects the brain and spinal cord. It damages the myelin sheath that surrounds and protects the nerve cells. Some of the symptoms of the disease includes weakness, numbness, blurred vision,…
- ナチュラルキラー細胞療法の世界市場（～2026年） Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destr…
- 犬幹細胞治療の世界市場（～2026年） The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic s…